These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
471 related articles for article (PubMed ID: 36319536)
41. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]. Katzmann JL; Laufs U Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570 [TBL] [Abstract][Full Text] [Related]
42. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large German-Austrian diabetes registry. Brandts J; Tittel SR; Bramlage P; Danne T; Brix JM; Zimny S; Heyer CHJ; Holl RW; Müller-Wieland D Diabetes Obes Metab; 2023 Dec; 25(12):3700-3708. PubMed ID: 37694759 [TBL] [Abstract][Full Text] [Related]
43. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
44. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517 [TBL] [Abstract][Full Text] [Related]
45. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. O'Keefe JH; DiNicolantonio JJ; Lavie CJ Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940 [TBL] [Abstract][Full Text] [Related]
49. Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease. Dayoub EJ; Eberly LA; Nathan AS; Khatana SAM; Adusumalli S; Navar AM; Giri J; Groeneveld PW J Am Heart Assoc; 2021 May; 10(9):e019331. PubMed ID: 33904340 [TBL] [Abstract][Full Text] [Related]
50. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377 [TBL] [Abstract][Full Text] [Related]
51. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772 [TBL] [Abstract][Full Text] [Related]
53. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels. Svensson MK; James S; Ravn-Fischer A; Villa G; Schalin L; Cars T; Gustafsson S; Hagström E Ups J Med Sci; 2024; 129():. PubMed ID: 38327639 [TBL] [Abstract][Full Text] [Related]
54. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
55. Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain. Cosin-Sales J; Sidelnikov E; Villamayor S; Fernández M; Merino-Montero S; Zamora A Adv Ther; 2023 Jun; 40(6):2710-2724. PubMed ID: 36525203 [TBL] [Abstract][Full Text] [Related]
56. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review. Chang Y; Eom S; Kim M; Song TJ Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734 [TBL] [Abstract][Full Text] [Related]
57. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Zheutlin AR; Derington CG; Herrick JS; Rosenson RS; Poudel B; Safford MM; Brown TM; Jackson EA; Woodward M; Reading S; Orroth K; Exter J; Virani SS; Muntner P; Bress AP Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008861. PubMed ID: 36252093 [TBL] [Abstract][Full Text] [Related]
58. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis. Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062 [TBL] [Abstract][Full Text] [Related]
59. Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort. Blaum C; Brunner FJ; Goßling A; Kröger F; Bay B; Lorenz T; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Seiffert M; Waldeyer C Clin Ther; 2021 Sep; 43(9):1583-1600. PubMed ID: 34462126 [TBL] [Abstract][Full Text] [Related]
60. Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias. Rached F; Santos RD Curr Cardiol Rep; 2021 Jun; 23(7):83. PubMed ID: 34081216 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]